Stevenage BioScience Catalyst
Real Estate · United Kingdom · 11-50 Employees
View Company Info for Free
Overview
Headquarters
The Incubator Gunnels Wood Rd, Stevenage...Phone Number
+44 2037095000Website
www.stevenagecatalyst.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Stevenage BioScience Catalyst
Stevenage Bioscience Catalyst is a premier location for therapeutic innovation, providing a supportive environment for growth within a networked community. It hosts a diverse range of companies, from major organizations like GSK to early-stage start-ups, all benefiting from world-class facilities and access to advanced technologies in cell and gene therapies. The campus fosters collaboration and interaction among entrepreneurs, offering various lab and office spaces tailored to different business needs. With a vibrant ecosystem, SBC aims to empower innovative SMEs and facilitate their success in the bioscience sector.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Stevenage BioScience Catalyst your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Stevenage BioScience Catalyst launches new products
Stevenage BioScience Catalyst, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Stevenage BioScience Catalyst is spiking on competitors!
Check if Stevenage BioScience Catalyst has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Stevenage BioScience Catalyst recently announced quarterly report
Funding: Get notified immidiatlly once Stevenage BioScience Catalyst has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Stevenage BioScience Catalyst
Click to see if Stevenage BioScience Catalyst had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined Stevenage BioScience Catalyst as Masked Content
Find 2 more new buyers
Compare Similar Companies to Stevenage BioScience Catalyst
Compare insights from companies similar to Stevenage BioScience Catalyst, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Stevenage BioScience Cata...
<$5M
11-50
Private
-
2012
N/A
Company Profile Activity
Activity Insights
Stevenage BioScience Catalyst is experiencing very low activity levels compared to other companies in the Real Estate sector.
What does this means?
Stevenage BioScience Catalyst is drawing exceptional interest within the Real Estate industry, suggesting notable developments or strong market momentum, learn more about Stevenage BioScience Catalyst.
Stevenage BioScience Catalyst Tech Stack
A closer look at the technologies used by Stevenage BioScience Catalyst
See more technologies
Most Recent Scoops
Open Position
Open Position
Executive Move
Executive Move
Stevenage BioScience Catalyst News & Media
NRG Therapeutics Announces First Participants Dosed in its First-in-Human Phase 1 Clinical Trial of NRG5051 Which is Being Developed as a Disease-modifying Treatment for ALS/MND and Parkinson’s
STEVENAGE, United Kingdom, Jan. 08, 2026 (GLOBE NEWSWIRE) -- NRG Therapeutics Ltd. (“NRG”), a clinical stage neuroscience company targeting a novel mechanism to rectify mitochondrial dysfunction in neurodegenerative diseases, is pleased to announce that the first participants have been dosed in its first-in-human Phase 1 clinical trial of its lead candidate NRG5051 which is being developed as a treatment for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) and Parkinson’s.NRG Therapeutics Announces Further Expansion with the Appointment of Paul Thompson as Chief Development Officer
STEVENAGE, United Kingdom, Dec. 01, 2025 (GLOBE NEWSWIRE) -- NRG Therapeutics Ltd. (“NRG”), an innovative neuroscience company targeting a novel mechanism to address mitochondrial dysfunction, is pleased to announce expansion of its team with the appointment of Paul Thompson, PhD, as Chief Development Officer (CDO).NRG Therapeutics Announces Senior Appointments as it Advances NRG5051 Towards First-in-Human Clinical Studies
STEVENAGE, United Kingdom, Oct. 23, 2025 (GLOBE NEWSWIRE) -- NRG Therapeutics Ltd. (“NRG”), an innovative neuroscience company targeting a novel mechanism to address mitochondrial dysfunction, is pleased to announce expansion of its team with the addition of three senior appointments in newly created roles: Sarah Almond as VP of Translational Biology; David Brocklebank as Director of Clinical Operations; and Kathryn Oliver as Director of Project Management.NRG Therapeutics Announces Oversubscribed £50m ($67m) Series B Financing to Deliver Clinical Data in Parkinson’s and Proof of Concept in ALS/MND
STEVENAGE, United Kingdom, Sept. 08, 2025 (GLOBE NEWSWIRE) -- NRG Therapeutics Ltd. (“NRG”), an innovative neuroscience company targeting a novel mechanism to address mitochondrial dysfunction, is delighted to announce the closing of its oversubscribed £50m Series B financing.
Read more news
Top Real Estate Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Stevenage BioScience Catalyst
Sign Up For FreeTo access detailed company insights
Stevenage Bioscience Catalyst is a premier location for therapeutic innovation, providing a supportive environment for growth within a networked community. It hosts a diverse range of companies, from major organizations like GSK to early-stage start-ups, all benefiting from world-class facilities and access to advanced technologies in cell and gene... Read More
